Drug Profile
Limaprost alfadex - Ono Pharmaceutical/Sumitomo Pharma
Alternative Names: Limaprost; Limaprost alphadex; ONO-1206; OP-1206; Opalmon; Opast; ProrenalLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma; Ono Pharmaceutical
- Developer Meiji Seika Pharma; Ono Pharmaceutical; Sumitomo Pharma; Yungjin Pharm Co
- Class Peripheral vasodilators; Prostaglandins; Small molecules; Unsaturated fatty acids; Vascular disorder therapies
- Mechanism of Action Platelet aggregation inhibitors; Prostaglandin E1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Intermittent claudication; Thromboangiitis obliterans
- Discontinued Carpal tunnel syndrome; Spondylosis
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 05 Mar 2020 Ono Pharmaceutical and Nichi-Iko Pharmaceutical enters into an licensing agreement to develop and market Limaprost alfadex for its improved formulation
- 29 Jun 2018 Preregisteration for Intermittent claudication in Thailand (PO) prior to June 2018